Targeting the PAX8‐AS1/GPX4 axis with a GPX4 inhibitor enhances the efficacy of gemcitabine and cisplatin in preclinical models, offering a promising strategy to overcome chemotherapy resistance in advanced intrahepatic cholangiocarcinoma. The gene discussed is PAX8; the disease is intrahepatic cholangiocarcinoma.